Waldron Private Wealth LLC lowered its position in Baxter International Inc (NYSE:BAX) by 40.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,882 shares of the medical instruments supplier’s stock after selling 1,960 shares during the period. Waldron Private Wealth LLC’s holdings in Baxter International were worth $212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. BKD Wealth Advisors LLC raised its stake in shares of Baxter International by 1.8% during the second quarter. BKD Wealth Advisors LLC now owns 41,331 shares of the medical instruments supplier’s stock valued at $3,052,000 after acquiring an additional 732 shares in the last quarter. FineMark National Bank & Trust raised its stake in shares of Baxter International by 6.0% during the second quarter. FineMark National Bank & Trust now owns 13,239 shares of the medical instruments supplier’s stock valued at $978,000 after acquiring an additional 753 shares in the last quarter. Drexel Morgan & Co. raised its stake in shares of Baxter International by 18.4% during the first quarter. Drexel Morgan & Co. now owns 4,887 shares of the medical instruments supplier’s stock valued at $318,000 after acquiring an additional 760 shares in the last quarter. Knowledge Leaders Capital LLC raised its stake in shares of Baxter International by 1.0% during the second quarter. Knowledge Leaders Capital LLC now owns 79,384 shares of the medical instruments supplier’s stock valued at $5,862,000 after acquiring an additional 786 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in shares of Baxter International by 84.4% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 1,748 shares of the medical instruments supplier’s stock valued at $126,000 after acquiring an additional 800 shares in the last quarter. 83.35% of the stock is owned by institutional investors and hedge funds.

NYSE:BAX traded up $0.16 during trading hours on Tuesday, reaching $72.36. The company’s stock had a trading volume of 10,006 shares, compared to its average volume of 3,144,721. The company has a market capitalization of $38.49 billion, a price-to-earnings ratio of 29.27, a price-to-earnings-growth ratio of 1.95 and a beta of 0.77. Baxter International Inc has a 12 month low of $60.53 and a 12 month high of $76.51. The company has a quick ratio of 2.00, a current ratio of 2.62 and a debt-to-equity ratio of 0.39.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period in the previous year, the company earned $0.63 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. sell-side analysts expect that Baxter International Inc will post 2.98 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 1st. Shareholders of record on Friday, August 31st will be issued a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 1.05%. The ex-dividend date of this dividend is Thursday, August 30th. Baxter International’s dividend payout ratio is currently 30.65%.

In other Baxter International news, SVP Scott Pleau sold 27,197 shares of Baxter International stock in a transaction on Monday, June 25th. The shares were sold at an average price of $73.57, for a total value of $2,000,883.29. Following the transaction, the senior vice president now directly owns 47,363 shares of the company’s stock, valued at $3,484,495.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carole J. Shapazian sold 5,400 shares of Baxter International stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $72.97, for a total transaction of $394,038.00. Following the completion of the transaction, the director now directly owns 15,248 shares in the company, valued at $1,112,646.56. The disclosure for this sale can be found here. Insiders sold 43,283 shares of company stock worth $3,196,371 over the last ninety days. Corporate insiders own 0.07% of the company’s stock.

BAX has been the subject of a number of recent research reports. Bank of America boosted their price objective on shares of Baxter International from $73.00 to $83.00 and gave the stock a “buy” rating in a research note on Tuesday, May 22nd. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a research note on Thursday, May 17th. Royal Bank of Canada reissued a “hold” rating and issued a $76.00 price objective on shares of Baxter International in a research note on Friday, July 27th. Stifel Nicolaus boosted their price objective on shares of Baxter International from $71.00 to $72.00 and gave the stock a “hold” rating in a research note on Monday, April 30th. Finally, Citigroup boosted their price objective on shares of Baxter International from $70.00 to $72.00 and gave the stock a “neutral” rating in a research note on Monday, April 30th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $76.00.

Baxter International Company Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: Diversification Important in Investing

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.